Effect of Early Enteral Tube Feeding Nutrition With an Immune Enhancing Diet in Severe Burn Patients
NCT ID: NCT00561210
Last Updated: 2013-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
57 participants
INTERVENTIONAL
2003-11-30
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
I
Total enteral tube feeding
Crucial
Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
II
Total enteral tube feeding
Sondalis HP
Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Crucial
Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
Sondalis HP
Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 15 \< age \< 70 years
* written informed consent
Exclusion Criteria
* corticoid or immuno-suppressive therapy
* HIV
* evolutive cancers
* pregnancy
* abdominal lesion
* hepatic or renal failure
15 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Société des Produits Nestlé (SPN)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cecile Chambrier
Role: STUDY_CHAIR
Hopital Edouard Herriot - Lyon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Pellegrin-Unites des brules
Bordeaux, , France
Hôpital Saint Luc - Service des brûlés
Lyon, , France
Hôpital Edouard Herriot
Lyon, , France
Hopital Hotel Dieu-Service des brules
Nantes, , France
Hopital Saint Antoine- Service des Brules
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCNF 0501
Identifier Type: -
Identifier Source: org_study_id